Hunt Companies Finance Trust Inc
Change company Symbol lookup
Select an option...
HCFT Hunt Companies Finance Trust Inc
BHV BlackRock Virginia Municipal Bond Trust
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
Go

Financials : Mortgage Real Estate Investment Trusts (REITs) | Small Cap Value
Company profile

Hunt Companies Finance Trust, Inc., formerly Five Oaks Investment Corp., is a real estate specialty finance company. The Company is focused on investing in a portfolio of mortgage-backed securities (MBS), mortgage loans and other real estate related investments. It is engaged in various real estate businesses, including multifamily ownership, non-bank agency lending, loan servicing, property management, construction, development and military housing. It offers a suite of products, including floating-rate transitional loans, fixed rate commercial real estate loans, mezzanine and preferred financing. It also provides Fannie, Freddie and federal housing administration (FHA) loans for multifamily, student housing, seniors, healthcare and manufactured housing. The Company is externally managed by Hunt Investment Management, LLC.

Closing Price
$2.81
Day's Change
0.02 (0.72%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.83
Day's Low
2.79
Volume
(Light)
Volume:
13,634

10-day average volume:
20,892
13,634

J&J halts studies for experimental influenza A treatment

9:45 am ET September 2, 2020 (MarketWatch)
Print

Shares of Johnson & Johnson (JNJ) were down 1.1% in trading on Wednesday after the company said it had halted late-stage clinical trials for pimodivir, which it was testing as a treatment for people with influenza A. J&J said interim analyses from a Phase 3 trial indicated that the investigational therapy when combined with the standard of care was unlikely to have an added benefit for patients hospitalized with the virus. It halted two trials, one testing pimodivir in outpatients and the other for hospitalized patients. The pimodivir program previously received funding from the Biomedical Advanced Research and Development Authority. J&J's stock is up 3.1% so far this year, while the S&P 500 has gained 9.2%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 02, 2020 09:45 ET (13:45 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.